Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
暂无分享,去创建一个
E. Felip | F. de Marinis | G. Altavilla | L. Paz-Ares | O. Molinier | J. Mazières | R. Rosell | M. Taron | N. Reguart | J. Ramírez | M. Sánchez-Ronco | M. Milella | C. Rolfo | B. Massuti | J. Sánchez | M. Provencio | P. Garrido | V. Gebbia | R. García-Campelo | C. Queralt | E. Cortesi | R. Gervais | D. Rodríguez-Abreu | M. Dómine | A. Vergnenègre | E. Carcereny | R. Palmero | R. García-Gómez | C. Pallarés | J. Sánchez | R. Porta | M. Cobo | F. Longo | T. Morán | A. Insa | R. Corre | I. Bover | A. Illiano | É. Dansin | J. De Castro | U. Jiménez | M. A. Moreno | J. Terrasa | J. Muñoz-Langa | J. Valdivia | D. Isla | N. Baize | G. Robinet | G. López-Vivanco | Lioba Ferrera-Delgado | P. Bombaron | R. Bernabé | A. Bearz | Á. Artal | A. Drozdowskyj | I. de Aguirre | M. Molina | J. de Castro | M. Moreno | B. Massutí
[1] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[2] N. Socci,et al. Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling , 2011, Science Translational Medicine.
[3] A. Gemma,et al. F1000 highlights , 2010 .
[4] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[5] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[6] H. Varmus,et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. , 2006, Genes & development.
[7] J M Lachin,et al. Implementation of group sequential logrank tests in a maximum duration trial. , 1990, Biometrics.
[8] Masahiro Fukuoka,et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] P. Jänne,et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. , 2006, Cancer cell.
[10] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[11] William Pao,et al. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer , 2010, Nature Reviews Cancer.
[12] Alona Muzikansky,et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] F. Hirsch,et al. A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[15] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[16] D. Tenen,et al. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. , 2007, Lung cancer.
[17] A. Nicholson,et al. Non-small-cell lung cancer , 2011, The Lancet.
[18] J. Mate,et al. Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations , 2011, Clinical Cancer Research.
[19] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[20] N. Hanna,et al. EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .
[21] Lin Huan,et al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .
[22] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[23] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[24] Koichi Goto,et al. Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.